BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

241 related articles for article (PubMed ID: 26398663)

  • 1. Spatial distribution of FMISO in head and neck squamous cell carcinomas during radio-chemotherapy and its correlation to pattern of failure.
    Zschaeck S; Haase R; Abolmaali N; Perrin R; Stützer K; Appold S; Steinbach J; Kotzerke J; Zips D; Richter C; Gudziol V; Krause M; Zöphel K; Baumann M
    Acta Oncol; 2015; 54(9):1355-63. PubMed ID: 26398663
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Residual tumour hypoxia in head-and-neck cancer patients undergoing primary radiochemotherapy, final results of a prospective trial on repeat FMISO-PET imaging.
    Löck S; Perrin R; Seidlitz A; Bandurska-Luque A; Zschaeck S; Zöphel K; Krause M; Steinbach J; Kotzerke J; Zips D; Troost EGC; Baumann M
    Radiother Oncol; 2017 Sep; 124(3):533-540. PubMed ID: 28843726
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Overlap of highly FDG-avid and FMISO hypoxic tumor subvolumes in patients with head and neck cancer.
    Mönnich D; Thorwarth D; Leibfarth S; Pfannenberg C; Reischl G; Mauz PS; Nikolaou K; la Fougère C; Zips D; Welz S
    Acta Oncol; 2017 Nov; 56(11):1577-1582. PubMed ID: 28849721
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Geometric analysis of loco-regional recurrences in relation to pre-treatment hypoxia in patients with head and neck cancer.
    Boeke S; Thorwarth D; Mönnich D; Pfannenberg C; Reischl G; La Fougère C; Nikolaou K; Mauz PS; Paulsen F; Zips D; Welz S
    Acta Oncol; 2017 Nov; 56(11):1571-1576. PubMed ID: 28891398
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of [(18)F]FMISO stratified dose-escalation on local control in FaDu hSCC in nude mice.
    Schütze C; Bergmann R; Brüchner K; Mosch B; Yaromina A; Zips D; Hessel F; Krause M; Thames H; Kotzerke J; Steinbach J; Baumann M; Beuthien-Baumann B
    Radiother Oncol; 2014 Apr; 111(1):81-7. PubMed ID: 24636842
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Robustness of quantitative hypoxia PET image analysis for predicting local tumor control.
    Mönnich D; Welz S; Thorwarth D; Pfannenberg C; Reischl G; Mauz PS; Nikolaou K; la Fougère C; Zips D
    Acta Oncol; 2015; 54(9):1364-9. PubMed ID: 26481464
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hypoxia-targeted radiotherapy dose painting for head and neck cancer using (18)F-FMISO PET: a biological modeling study.
    Chang JH; Wada M; Anderson NJ; Lim Joon D; Lee ST; Gong SJ; Gunawardana DH; Sachinidis J; O'Keefe G; Gan HK; Khoo V; Scott AM
    Acta Oncol; 2013 Nov; 52(8):1723-9. PubMed ID: 23317145
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of radiochemotherapy on T2* MRI in HNSCC and its relation to FMISO PET derived hypoxia and FDG PET.
    Wiedenmann N; Bunea H; Rischke HC; Bunea A; Majerus L; Bielak L; Protopopov A; Ludwig U; Büchert M; Stoykow C; Nicolay NH; Weber WA; Mix M; Meyer PT; Hennig J; Bock M; Grosu AL
    Radiat Oncol; 2018 Aug; 13(1):159. PubMed ID: 30157883
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fluorine-18-labeled fluoromisonidazole positron emission and computed tomography-guided intensity-modulated radiotherapy for head and neck cancer: a feasibility study.
    Lee NY; Mechalakos JG; Nehmeh S; Lin Z; Squire OD; Cai S; Chan K; Zanzonico PB; Greco C; Ling CC; Humm JL; Schöder H
    Int J Radiat Oncol Biol Phys; 2008 Jan; 70(1):2-13. PubMed ID: 17869020
    [TBL] [Abstract][Full Text] [Related]  

  • 10. 18F-fluoromisonidazole positron emission tomography before treatment is a predictor of radiotherapy outcome and survival prognosis in patients with head and neck squamous cell carcinoma.
    Kikuchi M; Yamane T; Shinohara S; Fujiwara K; Hori SY; Tona Y; Yamazaki H; Naito Y; Senda M
    Ann Nucl Med; 2011 Nov; 25(9):625-33. PubMed ID: 21720778
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Correlation between fluorodeoxyglucose hotspots on pretreatment positron emission tomography/CT and preferential sites of local relapse after chemoradiotherapy for head and neck squamous cell carcinoma.
    Chaput A; Calais J; Robin P; Thureau S; Bourhis D; Modzelewski R; Schick U; Vera P; Salaün PY; Abgral R
    Head Neck; 2017 Jun; 39(6):1155-1165. PubMed ID: 28263422
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Imaging of tumour hypoxia and metabolism in patients with head and neck squamous cell carcinoma.
    Zegers CM; van Elmpt W; Hoebers FJ; Troost EG; Öllers MC; Mottaghy FM; Lambin P
    Acta Oncol; 2015; 54(9):1378-84. PubMed ID: 26213313
    [TBL] [Abstract][Full Text] [Related]  

  • 13. High reproducibility of tumor hypoxia evaluated by 18F-fluoromisonidazole PET for head and neck cancer.
    Okamoto S; Shiga T; Yasuda K; Ito YM; Magota K; Kasai K; Kuge Y; Shirato H; Tamaki N
    J Nucl Med; 2013 Feb; 54(2):201-7. PubMed ID: 23321456
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prospective trial incorporating pre-/mid-treatment [18F]-misonidazole positron emission tomography for head-and-neck cancer patients undergoing concurrent chemoradiotherapy.
    Lee N; Nehmeh S; Schöder H; Fury M; Chan K; Ling CC; Humm J
    Int J Radiat Oncol Biol Phys; 2009 Sep; 75(1):101-8. PubMed ID: 19203843
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Potential of [18F]-fluoromisonidazole positron-emission tomography for radiotherapy planning in head and neck squamous cell carcinomas.
    Henriques de Figueiredo B; Merlin T; de Clermont-Gallerande H; Hatt M; Vimont D; Fernandez P; Lamare F
    Strahlenther Onkol; 2013 Dec; 189(12):1015-9. PubMed ID: 24173497
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The reoxygenation of hypoxia and the reduction of glucose metabolism in head and neck cancer by fractionated radiotherapy with intensity-modulated radiation therapy.
    Okamoto S; Shiga T; Yasuda K; Watanabe S; Hirata K; Nishijima KI; Magota K; Kasai K; Onimaru R; Tuchiya K; Kuge Y; Shirato H; Tamaki N
    Eur J Nucl Med Mol Imaging; 2016 Nov; 43(12):2147-2154. PubMed ID: 27251644
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dynamics of tumor hypoxia assessed by 18F-FAZA PET/CT in head and neck and lung cancer patients during chemoradiation: possible implications for radiotherapy treatment planning strategies.
    Bollineni VR; Koole MJ; Pruim J; Brouwer CL; Wiegman EM; Groen HJ; Vlasman R; Halmos GB; Oosting SF; Langendijk JA; Widder J; Steenbakkers RJ
    Radiother Oncol; 2014 Nov; 113(2):198-203. PubMed ID: 25434768
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Reproducibility of intratumor distribution of (18)F-fluoromisonidazole in head and neck cancer.
    Nehmeh SA; Lee NY; Schröder H; Squire O; Zanzonico PB; Erdi YE; Greco C; Mageras G; Pham HS; Larson SM; Ling CC; Humm JL
    Int J Radiat Oncol Biol Phys; 2008 Jan; 70(1):235-42. PubMed ID: 18086391
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The influence of changes in tumor hypoxia on dose-painting treatment plans based on 18F-FMISO positron emission tomography.
    Lin Z; Mechalakos J; Nehmeh S; Schoder H; Lee N; Humm J; Ling CC
    Int J Radiat Oncol Biol Phys; 2008 Mar; 70(4):1219-28. PubMed ID: 18313529
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Exploratory geographical analysis of hypoxic subvolumes using 18F-MISO-PET imaging in patients with head and neck cancer in the course of primary chemoradiotherapy.
    Bittner MI; Wiedenmann N; Bucher S; Hentschel M; Mix M; Weber WA; Grosu AL
    Radiother Oncol; 2013 Sep; 108(3):511-6. PubMed ID: 23849686
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.